US 2016/0237160 A1 · ANTI-TWEAKR ANTIBODIES AND USES THEREOF

Anti-tweakr antibodies and uses thereof

AssigneeBayer Pharma Aktiengesellschaft

InventorsChristian VOTSMEIER, Stefanie HAMMER, Uwe GRITZAN, Sandra BERNDT, Dmitry ZUBOV, Lars LINDEN, Sven CHRISTIAN, Axel HARRENGA, Jörg BIRKENFELD, Christoph FREIBERG, Sven GOLFIER, Andrea EICKER, Simone GREVEN, Beatrix STELTE-LUDWIG, Marian RASCHKE

Life of this patent

Estimating the term…

Abstract

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the TWEAKR (TNFRSF12A, FN14). The antibodies, accordingly, can be used to treat tumors and other disorders and conditions associated with expression of the TWEAKR. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for us.

Claims22

Dependent claims

An isolated anti-TWEAKR antibody or an antigen-binding fragment thereof, which specifically binds to the D at position 47 (D47) of TWEAKR as depicted in SEQ ID NO:169.

Dependencies are inferred from the claim text.

Facts

Application

14/898,455Filed 12 Jun 2014

Priority

EP 13172111.014 Jun 2013

Published

18 Aug 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification32 codes

C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61K 31/282
Compounds containing heavy metals: platinum compounds
A61K 31/44
Having six-membered rings with one nitrogen as the only ring hetero atom: non condensed pyridines; Hydrogenated derivatives thereof
A61K 31/4745
Ortho- or peri-condensed with heterocyclic ring systems: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines